A New Immunotherapy Combination for Metastatic Pancreatic Cancer
Researchers are looking at a combination of two types of monoclonal antibodies to treat advanced pancreatic cancer.
Researchers are looking at a combination of two types of monoclonal antibodies to treat advanced pancreatic cancer.
A platform clinical trial evaluates immunotherapy combinations with standard of care treatment for advanced pancreatic cancer.
Researchers are testing whether a vaccine can heighten the body’s immune response to pancreatic cancer after surgical removal of the tumor.
A clinical trial tests an investigational drug, immunotherapy, and radiation in combination against advanced pancreatic cancer.
CRISPR technology is used as part of an immunotherapy clinical trial for metastatic pancreatic cancer and other GI cancers.
An mRNA vaccine that works against KRAS mutations is being tested with and without immunotherapy for advanced or metastatic pancreatic cancer.
This trial tests the effectiveness of three different novel drugs, including immunotherapy, added to standard treatment for advanced pancreatic cancer.
A new clinical trial tests the safety of a monoclonal antibody and personalized cancer vaccine combined with chemotherapy after surgery to remove pancreatic cancer.
Researchers are looking at losartan and nivolumab combined with standard protocol of chemotherapy and radiation to see either drug or a combination is more effective.
Researchers are testing the use of tumor-infiltrating lymphocytes, a type of immunotherapy, against advanced pancreatic cancer.